ALNY has 36-month beta value of 0.30. Analysts have mixed views on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
The public float for ALNY is 125.78M, and currently, short sellers hold a 2.09% ratio of that float. The average trading volume of ALNY on May 24, 2024 was 576.04K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALNY) stock’s latest price update
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has experienced a decline in its stock price by -0.77 compared to its previous closing price of 149.38. However, the company has seen a fall of -0.78% in its stock price over the last five trading days. zacks.com reported 2024-05-03 that Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
ALNY’s Market Performance
ALNY’s stock has fallen by -0.78% in the past week, with a monthly rise of 3.15% and a quarterly drop of -6.57%. The volatility ratio for the week is 2.06% while the volatility levels for the last 30 days are 2.76% for Alnylam Pharmaceuticals Inc The simple moving average for the past 20 days is -0.94% for ALNY’s stock, with a -11.94% simple moving average for the past 200 days.
Analysts’ Opinion of ALNY
Many brokerage firms have already submitted their reports for ALNY stocks, with Goldman repeating the rating for ALNY by listing it as a “Neutral.” The predicted price for ALNY in the upcoming period, according to Goldman is $173 based on the research report published on February 16, 2024 of the current year 2024.
Wells Fargo gave a rating of “Equal Weight” to ALNY, setting the target price at $171 in the report published on December 08th of the previous year.
ALNY Trading at -0.77% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.28% of loss for the given period.
Volatility was left at 2.76%, however, over the last 30 days, the volatility rate increased by 2.06%, as shares surge +3.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.55% lower at present.
During the last 5 trading sessions, ALNY fell by -1.12%, which changed the moving average for the period of 200-days by -20.08% in comparison to the 20-day moving average, which settled at $149.86. In addition, Alnylam Pharmaceuticals Inc saw -22.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALNY starting from SHARP PHILLIP A, who sale 30,000 shares at the price of $151.34 back on Feb 29 ’24. After this action, SHARP PHILLIP A now owns 0 shares of Alnylam Pharmaceuticals Inc, valued at $4,540,071 using the latest closing price.
Greenstreet Yvonne, the Chief Executive Officer of Alnylam Pharmaceuticals Inc, sale 2,932 shares at $155.31 during a trade that took place back on Feb 28 ’24, which means that Greenstreet Yvonne is holding 48,128 shares at $455,357 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.84 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc stands at -0.17. The total capital return value is set at -0.06. Equity return is now at value -1500.66, with -9.20 for asset returns.
Based on Alnylam Pharmaceuticals Inc (ALNY), the company’s capital structure generated 1.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at -11.16. The interest coverage ratio of the stock is -1.38.
Currently, EBITDA for the company is -228.12 million with net debt to EBITDA at -10.25. When we switch over and look at the enterprise to sales, we see a ratio of 10.39. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.17.
Conclusion
To put it simply, Alnylam Pharmaceuticals Inc (ALNY) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
